| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
Sulfaclozine sodium targets dihydropteroate synthase, an enzyme in the bacterial folate synthesis pathway. By inhibiting this enzyme, the compound blocks the production of folic acid, which is essential for bacterial growth and replication. This makes Sulfaclozine sodium effective against a wide range of bacteria and protozoa. The compound is particularly effective against Eimeria species, which cause coccidiosis in poultry.
|
|---|---|
| ln Vitro |
Sulfachlorazine removal in UV/TiO2, UV/K2S2O8, and UV/TiO2/K2S2O8 systems. The adsorption of sulfachlorazine on the TiO2 surface is weak at pH 7 (<5%). However, it can be efficiently removed using UV/TiO2, UV/K2S2O8, and UV/TiO2/K2S2O8 in ultrapure water systems. Twelve sulfachlorazine by-products were also detected, and the reaction route demonstrated that conduction band electrons were obtained either directly or by the production of superoxide radicals, in addition to ·OH and SO4·− radicals [2].
In vitro, Sulfaclozine sodium demonstrates antibacterial and anticoccidial activities. It is effective against various bacterial pathogens and Eimeria species. The compound's activity is typically evaluated using broth microdilution methods to determine MIC values. Its anticoccidial activity is assessed using in vitro parasite cultures. The compound shows potent activity against poultry pathogens. |
| ln Vivo |
Sulfachlorazine (60 mg/kg; intravenously or orally; male broiler chickens) is mostly used to treat parasite and microbial illnesses of the gastrointestinal tract rather than systemic infections [1].
In vivo, Sulfaclozine sodium is used to treat coccidiosis in poultry. Dietary administration of Sulfaclozine reduces cecal lesion score and oocyst production in chick models of Eimeria infection. The compound is administered via intravenous injection or oral administration in broiler chickens at doses such as 60 mg/kg. It is primarily used to treat parasitic and microbial infections of the digestive tract. The compound's efficacy has been demonstrated in poultry production settings. |
| Enzyme Assay |
The cell-free assay for Sulfaclozine sodium involves evaluating its inhibitory activity against dihydropteroate synthase. Enzyme activity is measured by monitoring the conversion of substrates to products. Inhibition is assessed by incubating the enzyme with varying concentrations of Sulfaclozine sodium and measuring residual activity. IC50 values are determined from dose-response curves. The compound's antibacterial activity is also assessed using standard susceptibility testing methods.
|
| Cell Assay |
For in vitro cellular assays, Sulfaclozine sodium is typically dissolved in appropriate buffers and diluted in bacterial culture medium. Bacterial or protozoal cultures are treated with various concentrations of the compound. Bacterial growth is monitored by measuring optical density or colony counting. Parasite replication is assessed by counting oocysts or measuring parasite viability. MIC values are determined using broth microdilution methods.
|
| Animal Protocol |
Animal/Disease Models: 14 male broiler chickens (30 days old) [1]
Doses: 60 mg/kg Route of Administration: intravenous (iv) (iv)injection or oral administration (pharmacokinetic/PK/PK analysis) Experimental Results: Serum drug concentrations were 0.083, 0.50, 2, and 6 respectively , 24 and 72 hrs (hrs (hours)) after intravenous (iv) (iv)injection, the measured values were 99.62, 83.50, 72.68, 58.43, 38.66 and 13.14 μg/mL respectively. Oral determinations were 4.33, 7.95, 16.46, 22.88, 16.03 and 5.74 μg/mL respectively. In vivo animal studies for Sulfaclozine sodium are conducted in poultry models of coccidiosis. The compound is administered via dietary inclusion or oral gavage. Cecal lesion scores are evaluated at necropsy. Oocyst production is measured in feces. Body weight and feed conversion are monitored as measures of overall health and productivity. Efficacy is compared to untreated controls. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Sulfaclozine sodium include a molecular weight of 306.70 g/mol and molecular formula C10H8ClN4NaO2S. The compound is soluble in DMSO (≥58.9 mg/mL), ethanol (≥4.85 mg/mL), and water (≥24.75 mg/mL). As a sulfonamide antibiotic, it is well-absorbed and distributed. Detailed ADME parameters are available from veterinary pharmacology studies. The compound is stored at appropriate conditions as a research reagent.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Sulfaclozine sodium has been characterized in veterinary studies. As a sulfonamide antibiotic, potential toxicities may include hypersensitivity reactions and effects on hematopoiesis. The compound is used in veterinary medicine at carefully controlled doses. Standard safety precautions should be followed when handling this compound. It is intended for veterinary and research use only.
|
| References |
[1]. Sentepe I, et al. Pharmacokinetic of sulfaclozine in broiler chickens. Food Chem Toxicol. 2010 Jan;48(1):448-451.
[2]. Ismail L, et al. Effect of water constituents on the degradation of sulfaclozine in the three systems: UV/TiO2, UV/K2S2O8, and UV/TiO2/K2S2O8. Environ Sci Pollut Res Int. 2018 Jan;25(3):2651-2663. |
| Additional Infomation |
Sulfaclozine sodium is a sulfonamide antimicrobial agent with potent anticoccidial and antibacterial activities. It is commonly used in veterinary medicine to treat coccidiosis in poultry and is particularly effective against Eimeria species. Dietary administration of Sulfaclozine reduces cecal lesion scores and oocyst production in infected chicks. The compound is a veterinary medicine and research tool for studying parasitic infections.
|
| Molecular Formula |
C10H8CLN4NAO2S
|
|---|---|
| Molecular Weight |
306.7039
|
| Exact Mass |
305.995
|
| CAS # |
23307-72-4
|
| Related CAS # |
Sulfaclozine;102-65-8
|
| PubChem CID |
42623021
|
| Appearance |
Light yellow to yellow solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
19
|
| Complexity |
370
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
NIUFFODHMKLSCH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H8ClN4O2S.Na/c11-9-5-13-6-10(14-9)15-18(16,17)8-3-1-7(12)2-4-8;/h1-6H,12H2;/q-1;+1
|
| Chemical Name |
sodium;(4-aminophenyl)sulfonyl-(6-chloropyrazin-2-yl)azanide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL (~163.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2605 mL | 16.3026 mL | 32.6052 mL | |
| 5 mM | 0.6521 mL | 3.2605 mL | 6.5210 mL | |
| 10 mM | 0.3261 mL | 1.6303 mL | 3.2605 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
